Reviewed by Michael Gill, B. Sc.
Image of RADLAB at Innovation Park in Tallahassee, United States.
Phase-Based Progress Estimates
1
Effectiveness
1
Safety

Interventionfor Phobia, Social

< 18
All Sexes
Anxiety disorders are the most common form of psychopathology, and frequently begin in childhood, resulting in lifelong impairment. Increased brain activity after making mistakes, as reflected by the error-related negativity (ERN), is observed in people with anxiety disorders, even before disorder onset. The ERN is therefore of great interest as a potentially modifiable risk factor for anxiety. However, methodological issues can make the ERN difficult to measure. Increased brain activity in response to a balance disturbance, as reflected by the balance N1, resembles the ERN, but does not share its methodological issues. The investigators' preliminary data demonstrate that the balance N1 and the ERN are associated in amplitude in adults, suggesting they may depend on the same brain processes. The balance N1 has never been investigated in individuals with anxiety disorders, but it increases in amplitude within individuals under anxiety-inducing environmental contexts. Further, balance and anxiety are related in terms of brain anatomy, daily behavior, disorder presentation, and response to treatment. The present investigation will measure the ERN and the balance N1 in children (ages 9-12) with anxiety disorders, and further, how these brain activity measures change in response to a brief, 45-minute, computerized psychosocial intervention that was developed to reduce reactivity to errors, and has been shown to reduce the ERN. The investigators will recruit approximately 80 children with anxiety disorders, half of whom will be randomly assigned to the active intervention condition. The other half will be assigned to an active control condition, consisting of a different 45-minute computerized presentation. Participants assigned to the control condition can access the computerized intervention after participation in the study. The purpose of this investigation is to test the hypothesis that the balance N1 and the ERN will be reduced to a similar extent after the intervention, to demonstrate that these brain responses arise from shared brain processes. Transfer of the effect of the psycho-social intervention to the balance N1 would provide insight into prior work demonstrating that balance training can alleviate anxiety in young children, and well-documented benefits of psychotherapy to balance disorders. Collectively, these data may guide the development of multidisciplinary interventions for the prevention and treatment of anxiety disorders in children.
Recruiting
Has No Placebo
RADLAB at Innovation ParkGreg Hajcak, PhD
25 Ocd Clinical Trials Near Me
Top Cities for Ocd Clinical Trials
Ocd Clinical Trials by Phase of Trial
Phase < 1 Ocd Clinical Trials
1Active Ocd Clinical Trials
1Number of Unique Treatments
1Number of Active Locations
Immediate Psilocybin
Ocd Clinical Trials by Age Group
< 18 Ocd Clinical Trials
9Active Ocd Clinical Trials
Cognitive Behavioral Therapy-Email (iCBT-E)Cognitive Behavioral Teletherapy LTAVR SystemContinued SRIInterventionTranscranial Direct Current StimulationNaproxen SodiumExposure & Response Prevention (EX/RP) and when indicated medication treatment
Top Treatments for Ocd Clinical Trials
Treatment Name
Active Ocd Clinical Trials
All Time Trials for Ocd
First Recorded Ocd Trial
Celecoxib
2
2
2021
Cognitive bias modification for interpretation bias
2
2
2019
Focused Ultrasound
2
2
2017
Troriluzole
2
2
2020
BX Pulsar 1002
1
1
2022
Recently Completed Studies with FDA Approved Treatments for Ocd
Treatment
Year
Sponsor
Psilocybin 300 mcg/kg
2019
University of Arizona

What is Obsessive-compulsive Disorder?

Obsessive-compulsive disorder or OCD is a mental condition wherein a person may have habits or sensations that can be regarded as an extreme compulsion to do something without relent. These urges and thoughts can occur again and again.

Though people with OCD may do these things repeatedly, they often do not enjoy doing it and may take a lot of time out of their day, affecting their social and work lives.

These habits can come in many forms, but the most common ones include:

  • Not being able to stop you from securing locks, light switches, ovens, or stoves and having an overall lack of security.
  • Being paranoid that you may have certain medical conditions.
  • Germaphobia and being too uptight with handling dirty things.
  • Being obsessed with symmetry and fixing the order of things, being bothered by things out of balance or out of order.
  • Intrusive thoughts and not being able to abandon them.

Why is OCD Being Studied In Clinical Trials?

OCD has a lot of real-life implications, including not functioning properly, struggling to maintain focus and the onset of many mental health issues. Many OCD clinical trials aim to study the brain further and how it controls people with OCD, as well as going into the memories and trauma that person has that may factor into the diagnosis.

How Does OCD Treatment Work?

OCD treatment often goes one or two ways, psychological therapy or medication. Therapy involves working with a professional and licensed therapist to help discuss your problems and analyze them to the point that you may recognize what’s wrong and how you can fight them.

Most people find dissecting their fears, obsessions, and anxiety difficult at first, and can top about 10 hours of therapy per month, which will only extend the more severe your OCD is.

Medication is another route a person can take, with most doctors prescribing an antidepressant called SSRIs or selective serotonin reuptake inhibitors. This

antidepressant helps symptoms by injecting serotonin into your brain. Though it may take some time to take effect, it has shown to be an effective method of putting OCD at ease. Intake can take a few months up until a year. Side effects may arise from gradual intake, and it is recommended to check up with your doctor again to make sure that the symptoms are not getting out of hand.

What Are Some of the Breakthrough Clinical Trials Involving OCD?

2016 - a study in biological psychiatry done at Duke University may have found a breakthrough in muting OCD symptoms. Researchers at Duke Univesity have been breaking down the biological background and origin of depressive disorders, finding a link to OCD through overstimulated frontostriatal activity. Standard treatment for OCD and other depressive disorder take up a lot of time to take effect, ranging from at least three (3) weeks to several months. This is because serotonin reuptake inhibitors take a long time to reach and activate inside the brain, which scientists at Duke University believe to be from a lack of understanding of the mechanisms. This study is significant because there might be a faster, more efficient way to identify chemical imbalances that cause OCD and use a better remedy for those abnormalities.

2019 - Artificial Intelligence has seen a lot of improvements in the past few years, and it is no different in the field of medicine and depression treatment. AI technology can now pinpoint the chemicals in the brain that are associated with a neural activity that causes depression and OCD. Through this, antibodies can be administered you counter-act these chemical imbalances. This study is significant because it finds empirical problems and has empirical solutions, having an accurate diagnosis as well as accurate treatment of OCD.

Who Are The Key Opinion Leaders On OCD Clinical Trial Research?

Elizabeth Mcingvale is the current director at McLean OCDI Houston while also being a lecturer at Harvard University. She has especially put a focus on obsessive-compulsive disorder and has founded the Peace of Mind Foundation, which offers self-help in six different languages and has found over 4000 adherents.

Dean Mckay is a professor of psychology at Fordham University, and he has his own research lab called the compulsive, obsessive, and anxiety program, where he actively engages in research with his students on OCD.

Top Hospitals For OCD Clinical Trials

The Baylor College of Medicine is currently holding ten (10) active OCD clinical trials, having started trials in 2017. This makes it the current top hospital to go to according to Power’s data, and with it being one of the largest medical centers in the world, its programs are trusted.

To see more of the hospitals for OCD Clinical Trials, see the list below.

Top Treatments for OCD Clinical Trials

According to Power’s data, there are four top treatments for OCD clinical trials, namely Celecoxib, cognitive bias modification for interpretation bias, focused ultrasound, and troriluzole, with two (2) active trials each.

To see more of the top treatments for OCD clinical trials, see the list below.

Top Cities for OCD Clinical Trials

With the Baylor College of Medicine being located in Houston, this makes the city the top destination for OCD clinical trials as it has a total of 16 active trials.

To see more top cities for OCD clinical trials, see the list below.

How Many OCD Clinical Trials are Open to Youth and/or Seniors?

Power’s Data has shown that for OCD patients below the age of 18, there are seven (7) active trials recruiting. For patients above the age of 18, a large selection of 40 active trials is active.

To see more OCD clinical trials, see the list below.

Most Recent OCD Clinical Trials

Power’s data has shown that the most recent one is Active tDCS for obsessive-compulsive disorder, which started last September 1st, 2022.

To see more recent OCD clinical trials, see the list below.

Resources:

https://www.nimh.nih.gov/health/topics/obsessive-compulsive-disorder-ocd

https://www.webmd.com/mental-health/obsessive-compulsive-disorder

https://www.inverse.com/article/18751-ocd-research-symptoms-minutes

https://www.brainsway.com/knowledge-center/breakthroughs-in-ocd-treatment/, https://www.biologicalpsychiatryjournal.com/article/S0006-3223(16)32380-0/fulltext

About The Author

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 11th, 2021

Last Reviewed: October 6th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References1 Ware J Jr, Kosinski M, Keller SD. A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care. 1996 Mar;34(3):220-33. https://pubmed.ncbi.nlm.nih.gov/86280422 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59 Suppl 20:22-33;quiz 34-57. Review. https://pubmed.ncbi.nlm.nih.gov/98815383 HAMILTON M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960 Feb;23:56-62. https://pubmed.ncbi.nlm.nih.gov/143992724 George MS, Lisanby SH, Avery D, McDonald WM, Durkalski V, Pavlicova M, Anderson B, Nahas Z, Bulow P, Zarkowski P, Holtzheimer PE 3rd, Schwartz T, Sackeim HA. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010 May;67(5):507-16. doi: 10.1001/archgenpsychiatry.2010.46. https://pubmed.ncbi.nlm.nih.gov/204398325 Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979 Apr;134:382-9. https://pubmed.ncbi.nlm.nih.gov/4447886 HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32(1):50-5. https://pubmed.ncbi.nlm.nih.gov/136385087 George MS, Wassermann EM, Williams WA, Callahan A, Ketter TA, Basser P, Hallett M, Post RM. Daily repetitive transcranial magnetic stimulation (rTMS) improves mood in depression. Neuroreport. 1995 Oct 2;6(14):1853-6. https://pubmed.ncbi.nlm.nih.gov/85475838 Pascual-Leone A, Rubio B, Pallardó F, Catalá MD. Rapid-rate transcranial magnetic stimulation of left dorsolateral prefrontal cortex in drug-resistant depression. Lancet. 1996 Jul 27;348(9022):233-7. https://pubmed.ncbi.nlm.nih.gov/86842019 Holtzheimer PE 3rd, McDonald WM, Mufti M, Kelley ME, Quinn S, Corso G, Epstein CM. Accelerated repetitive transcranial magnetic stimulation for treatment-resistant depression. Depress Anxiety. 2010 Oct;27(10):960-3. doi: 10.1002/da.20731. https://pubmed.ncbi.nlm.nih.gov/2073436010 Chung SW, Hoy KE, Fitzgerald PB. Theta-burst stimulation: a new form of TMS treatment for depression? Depress Anxiety. 2015 Mar;32(3):182-92. doi: 10.1002/da.22335. Epub 2014 Nov 28. Review. https://pubmed.ncbi.nlm.nih.gov/25450537